The Full Wiki

More info on Radafaxine

Radafaxine: Wikis

  

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Radafaxine
Systematic (IUPAC) name
(+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethylmorpholin-2-ol
Identifiers
CAS number 106083-71-0
ATC code none
PubChem 9838996
Chemical data
Formula C 13H18ClNO2  
Mol. mass 292.20 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes  ?

Radafaxine is drug candidate designated GW-353,162[1] by GlaxoSmithKline, investigated for treatment of restless leg syndrome and as an NDRI antidepressant. GlaxoSmithKline was targeting Radafaxine for regulatory filing in 2007,[2] but development was discontinued in 2006 due to "poor test results".[3]

Contents

Chemistry

It is a potent metabolite of bupropion, the compound in GlaxoSmithKline's Wellbutrin. More specifically, "6-hydroxybupropion" is an analogue of bupropion, and radafaxine is an isolated isomer of 6-hydroxybupropion.[4]

Therefore, radafaxine builds on at least some of the properties of bupropion in humans.[5]

Effects

Presently in various clinical trials, radafaxine is being studied as a treatment for clinical depression, obesity, and neuropathic pain. Radafaxine is described as a norepinephrine-dopamine reuptake inhibitor (NDRI).

Unlike bupropion (which has a slightly higher effect on dopamine reuptake), radafaxine seems to have a higher potency on norepinephrine. This, according to GlaxoSmithKline, may account for the increased effect of radafaxine on pain and fatigue.[6]

Radafaxine has about 70% of bupropion's efficacy in blocking dopamine reuptake, and 392% of efficacy in blocking norepinephrine reuptake.[7] [8]

At least one study suggests that radafaxine has a low abuse potential similar to bupropion.[9]

See also

References

  1. ^ Restless Legs Syndrome: First Approval
  2. ^ {1} Reviews Novel Therapeutics For CNS Disorders And Confirms Strong Pipeline Momentum - News, Search Jobs, Events
  3. ^ GSK breakthrough on bird flu vaccine - Business News, Business - Independent.co.uk
  4. ^ MeSH radafaxine
  5. ^ GlaxoSmithKline Reviews Novel Therapeutics for CNS Disorders and Confirms Strong Pipeline Momentum
  6. ^ Microsoft PowerPoint - slides_05_burch.ppt
  7. ^ ^ Xu H, Loboz KK, Gross AS, McLachlan AJ (2007). "Stereoselective analysis of hydroxybupropion and application to drug interaction studies". Chirality 19 (3): 163–70. doi:10.1002/chir.20356. PMID 17167747.
  8. ^ ^ Bondarev ML, Bondareva TS, Young R, Glennon RA (2003). "Behavioral and biochemical investigations of bupropion metabolites". Eur J Pharmacol 474 (1): 85–93. doi:10.1016/S0014-2999(03)02010-7. PMID 12909199.
  9. ^ Radafaxine







Got something to say? Make a comment.
Your name
Your email address
Message